Atrial Flutter

The prevalence of left atrial thrombus is high in certain anticoagulated patients with atrial fibrillation, which suggests a role for transesophageal echocardiogram imaging before procedures in that population, researchers reported.

Tempus announced the FDA has granted a breakthrough device designation to its ECG analysis platform for the identification of atrial fibrillation or atrial flutter, developed in collaboration with Geisinger.

New-onset atrial fibrillation and atrial flutter are as common in hospitalized patients with influenza as with COVID-19, suggesting the connection between the arrhythmias and COVID-19 is related to the general inflammatory state.

Among patients hospitalized with COVID-19, atrial fibrillation and atrial flutter are common and are associated with worse outcomes, according to findings presented at the virtual American Heart Association Scientific Sessions.

“Cryoconvergent” hybrid ablation for atrial fibrillation may significantly reduce risk for recurrent AF and AF burden in patients with persistent AF or long-standing persistent AF, researchers reported.

Hypnosis was superior to placebo to alleviate pain and reduce the consumption of morphine during atrial flutter ablation, researchers found in a prospective, randomized study.

Boston Scientific announced it received clearance from the FDA for the company’s new insertable cardiac monitor system.

Ambulatory telemetry monitors for patients with COVID-19 being treated with hydroxychloroquine and/or azithromycin provided real-time alerts to electrophysiologists and may improve their ability to monitor QTc changes and arrhythmias, reduce the need for serial ECGs and better allocate resources, researchers reported.

In patients with nonobstructive hypertrophic cardiomyopathy, treatment with mavacamten was well tolerated and reduced biomarkers of cardiac injury and wall stress, according to results of the phase 2 MAVERICK-HCM study.